GEHC vs LNTH
GEHC: GE HealthCare is a leading global medical technology provider delivering advanced diagnostic imaging, clinical systems, and intelligent digital solutions to healthcare providers worldwide. LNTH: Lantheus is a specialist in diagnostic imaging agents and radiopharmaceuticals that help clinicians visualize cardiovascular conditions and oncological disease states.
Side-by-side fundamentals
| Metric | GEHC | LNTH | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $64.22 | $100.12 | |
| Market cap | $29.2B | $6.5B | |
| P/E as of 2026-10-08 | 14.77 | 24.22 | GEHC lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 5.81 | n/a | |
| Net margin FY2025, SEC XBRL | +10.1% | +15.2% | LNTH higher |
| Gross margin FY2025, SEC XBRL | +40.0% | +61.1% | LNTH higher |
| Operating margin FY2025, SEC XBRL | +13.4% | +20.2% | LNTH higher |
| ROE FY2025, SEC XBRL | +20.1% | +21.4% | LNTH higher |
| ROA FY2025, SEC XBRL | +5.6% | +10.5% | LNTH higher |
| Debt / equity as of 2026-09-03 | 0.92 | 0.44 | LNTH lower |
| Revenue growth (YoY) as of 2026-09-03 | +6.5% | +2.4% | GEHC higher |
| Revenue CAGR (3y) SEC XBRL | +4.0% | +18.1% | LNTH higher |
| Dividend yield as of 2026-09-03 | +0.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 3 | 0 | GEHC higher |
| Beta as of 2026-09-03 | 1.08 | 0.38 | |
| 1-year return as of 2026-10-08 close | -14.5% | +87.0% | LNTH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.